• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

ACR responds to CMS Medicare Part D and Medicare Advantage proposed rule

Bioengineer by Bioengineer
January 24, 2019
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Rheumatology leaders urge CMS to adopt safeguards protecting Medicare Advantage beneficiaries from step therapy; encourage more price transparency in Part D

ATLANTA, GA – In comments submitted to the Centers for Medicare and Medicaid Services (CMS), the American College of Rheumatology (ACR) expressed its continuing concern with a recent CMS policy allowing Medicare Advantage (MA) plans to utilize step therapy for Part B drugs. In the comment letter, rheumatology leaders urged the agency to establish safeguards to protect beneficiaries from potential harm.

“While we appreciate the agency’s efforts to make prescription medications more affordable, we have serious concerns regarding the decision to allow Medicare Advantage plans to implement step therapy for Part B drugs and cross-manage Part B and D drug utilization,” said Paula Marchetta, MD, MBA, president of the ACR. “We begin the 2019 benefit year with no safeguards in place to protect beneficiaries from changes that could seriously threaten their access to needed medications. At a minimum, CMS should immediately issue updated guidance that will clarify patient protections for the current year and beyond.”

Step therapy, sometimes known as “fail first”, is a utilization management technique employed by most health insurers that forces patients to try medications preferred by the insurance company before approving the medication prescribed by the patient’s doctor – even when there is no evidence the “insurer preferred” option will be effective. This practice often leads to delays in patient access to appropriate, evidence-based treatment and undermines the clinical expertise and judgment of health care providers.

In its comments to the agency, the ACR urged CMS to establish the following safeguards before moving forward with its step therapy policy:

  • Make clear that a patient’s provider must determine if a patient “fails” a treatment. This
    decision should not be made by another entity such an insurance company.

    • Provide exceptions to step therapy if:
    • The treatment is contraindicated for a patient’s specific condition.
    • The provider determines, based on medical evidence, that the treatment is likely to be
      ineffective, likely to cause a harmful reaction, or impede the patient’s ability to
      perform daily activities or responsibilities and/or adhere to the treatment plan.
    • The provider believes the new treatment will put the patient’s life in jeopardy or
      irreparably harm his/her physical or sensory functions.
  • Require MA plans to disclose that Part B drugs may be subject to step therapy in the
    plan’s Annual Notice of Change and Evidence of Coverage Documents.

  • Implement a 365-day “lookback” period for Part B therapies instead of the current 108-
    day period used in Medicare Part D plans.

  • Preclude plans from implementing step therapy via a different utilization management
    process such as prior authorization.

  • Increase monitoring of plans’ usage of utilization management practices and require
    that all denials include the clinical rationale for the decision while making clear a
    beneficiary’s appeal rights.

The ACR also commented on CMS’ decision to make changes to the Part D program, namely the agency’s new requirement that drug pricing information and lower-cost therapeutic alternatives be included in the plan’s Explanation of Benefits document. The ACR commended CMS for implementing a ban on “gag clauses” that prevent pharmacies from disclosing if a drug’s cash price is lower than the price with insurance. It also urged the agency to consider establishing common definitions for terms used during plan negotiations with Pharmacy Benefit Managers.

“The ACR is dedicated to ensuring that rheumatologists and rheumatology care professionals have the resources they need to provide patients with appropriate, high-quality care and that safe and effective treatments be available to all patients at the lowest possible cost,” Dr. Marchetta concluded. “We appreciate the opportunity to respond to this proposed rule and look forward to serving as a resource for the agency as it continues its work.”

###

About the American College of Rheumatology

The American College of Rheumatology (ACR) is the nation’s leading advocacy organization for the rheumatology care community, representing more than 7,700 U.S. rheumatologists and rheumatology health professionals who are committed to improving healthcare for Americans living with rheumatic diseases.

Media Contact
Jocelyn Givens
[email protected]
404-929-4810

Tags: Health CareHealth Care Systems/ServicesHealth ProfessionalsInsuranceMedicine/HealthPolicy/EthicsPublic HealthScience/Health and the Law
Share12Tweet8Share2ShareShareShare2

Related Posts

Old Mitochondria Drive Stem Cell Niche Renewal

Old Mitochondria Drive Stem Cell Niche Renewal

August 3, 2025
How the Brain Integrates Multimodal Cues for Direction

How the Brain Integrates Multimodal Cues for Direction

August 3, 2025

LONP1 Controls Mitochondrial Folding, Impacts Diabetes

August 3, 2025

Astrocyte Fate in Mouse Septum Driven by Origins, Signals

August 3, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    48 shares
    Share 19 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Predicting Hidden Cervical Cancer via Cytology, ECC

High-Capacity Phase-Sensitive Amplification In Fiber

Old Mitochondria Drive Stem Cell Niche Renewal

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.